Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 5 Genitourinary 4 Gastrointestinal 2 Tumor-Agnostic 1 Thoracic 1 Sarcoma 1 Breast 1

Conditions

Ovarian Neoplasms 1 Carcinosarcoma 1

Interventions

Cyclophosphamide 93 Doxorubicin 92 Radiotherapy 87 Temozolomide 69 Filgrastim 58 Ifosfamide 55 Bevacizumab 55 Etoposide 48 Gemcitabine 44 Imatinib Mesylate 43 Vincristine 40 pembrolizumab 35 pazopanib 34 Peripheral Blood Stem Cell Transplantation 31 Methotrexate 31 Nivolumab 30 Carboplatin 30 fludarabine phosphate 29 Irinotecan 29 Cisplatin 28 Paclitaxel 26 Melphalan 26 Magnetic Resonance Spectroscopy 26 Docetaxel 25 Busulfan 25 Trabectedin 24 apatinib 22 Specimen Handling 21 Sirolimus 21 Antilymphocyte Serum 21

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × pamiparib × Sarcoma × Clear all

NCT03933761 2021-08-10

PRECISE

Australia New Zealand Gynaecological Oncology Group

Phase 2 Withdrawn

GynecologicSarcoma

Carcinosarcoma, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡